Amarin Q2 Revenue Drops 42% to $42.2M as Licensing Income Evaporates; Cash Runway Remains Strong at $314.6M
AMRN is trading near its 52-week low of $12.96 (9.3% above the low).
Summary
Amarin's Q2 2026 revenue fell 42% to $42.2M, with product sales down 16% and licensing income nearly vanishing. The company lost $7.65M but holds $314.6M in cash and investments. Key legal updates include a Supreme Court loss in the Hikma patent case and settlement of antitrust class actions.
Key Events · Earnings and Guidance · AMRN
-
Revenue Plunges 42%
Total net revenue fell to $42.2M from $72.7M a year ago, driven by a $23M drop in licensing and royalty revenue (which included a $25M Recordati upfront payment in Q2 2025) and a 16% decline in product revenue to $39.1M.
-
Net Loss Narrows but Remains
Net loss was $7.65M, improved from $14.1M a year ago, as restructuring-driven cost cuts reduced selling, general and administrative expenses by 43%.
-
Strong Cash Position
Cash, cash equivalents, and short-term investments totaled $314.6M at quarter-end, with no debt outstanding. Management believes this is sufficient to fund operations for at least 12 months.
-
Supreme Court Loss in Hikma Patent Case
On June 4, 2026, the U.S. Supreme Court reversed the Federal Circuit, finding Amarin failed to state a claim for active inducement of patent infringement against Hikma, a major legal setback.
Analysis · AMRN · Life Sciences
Amarin's second-quarter results show a sharp revenue decline driven by the absence of a $25M upfront licensing payment from Recordati recognized in the prior year. Product revenue also fell 16% to $39.1M, pressured by lower U.S. net pricing and the transition of European operations to Recordati. The company remains unprofitable with a $7.65M net loss, but cost controls from the completed restructuring kept operating expenses down. Cash and investments of $314.6M provide ample runway, and the company has no debt. The filing also discloses the Supreme Court's June 4, 2026 reversal in the Hikma patent case, a major legal setback, and the settlement of antitrust class actions. These legal updates, combined with the revenue trajectory, are critical for assessing Amarin's post-generic-competition future.
At the time of this filing, AMRN was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $292.7M. The 52-week trading range was $12.96 to $20.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.